HDAC9 and Miyoshi myopathy: 888 (PARP inhibitor), AICAR (AMPK activator), ATRA (all-trans retinoic acid), dasatinib (tyrosine kinase inhibitor), AZD8055 (mTOR inhibitor), erlotinib (EGFR inhibitor), etoposide, MG.132 (proteasome inhibitor), parthenolide (HDAC inhibitor), rapamycin (mTORC1 complex inhibitor), and thapsigargin (ATPase inhibitor) were also lower in high-risk score group (Fig. 8), which might provide novel insights into MM treatment.